Mirati Therapeutics, Inc. (NASDAQ:MRTX) Q4 2022 Earnings Call Transcript

Jay Olson: Hi, thank you for the update and thanks for taking the questions. For 1133, can you talk about the lessons learned or read across from Revolution Medicines preliminary data last night, which included some G12D patients? And then for sitravatinib, can you just talk about your expectations for the SAPPHIRE readout in the second quarter and since you’re focused on the launch of KRAZATI, are you doing any pre-launch planning for sitravatinib given the similar indications for Sitra and KRAZATI? Thank you.

James Christensen: Yes. I think regarding Rev Med, we are paying attention to what they’re doing, but we’ll probably not comment on Rev Med at this point in time other than to say we continue to be excited about advancing 1133 and patients here imminently. And we also continue to explore in the preclinical setting, different types of KRAS inhibitors, including those that inhibit different spectrums of mutations, including the G12C mutation G13D and Q61 mutations. So, we will be continuing to pursue this and when appropriate can update on that front.

Alan Sandler: And on the Sitravatinib question. As a reminder, we’ll see the final analysis for the SAPPHIRE study in Q2 of this year as events are tracking as expected. And regards to any of the pre-launch work, I think, the learnings will take from launching adagrasib will be key here. We have a very experienced lung cancer team and we believe that we’ll be able to leverage the existing team and existing infrastructure to be able to launch Sitravatinib, but a high degree of expertise as well as at a high rate. So, no need for a lot of market building in that from that we think the mechanism is pretty well recognized and we have the team in place to hopefully on the back of a positive study move to file and then ultimately to promote the product very quickly.

Operator: There are no further questions at this time, Mr. Meek, I will turn the conference back to you for any additional or closing remarks.

David Meek: Thank you, Cynthia, and thank you everyone for joining us this afternoon. We appreciate your interest in Mirati and we look forward to sharing additional updates with you.